

Martin H Voss

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7444844/publications.pdf>

Version: 2024-02-01

30
papers

2,145
citations

430874

18
h-index

552781

26
g-index

31
all docs

31
docs citations

31
times ranked

3792
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. <i>Clinical Cancer Research</i> , 2022, 28, 738-747. | 7.0 | 11 |
| 2 | Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial. <i>Clinical Cancer Research</i> , 2022, 28, 1540-1548. | 7.0 | 21 |
| 3 | Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Nonâ€œClear-Cell Renal Cell Carcinoma and Genomic Correlates. <i>Journal of Clinical Oncology</i> , 2022, 40, 2333-2341. | 1.6 | 72 |
| 4 | A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 3032-3041. | 7.0 | 7 |
| 5 | Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2021, 124, 237-246. | 6.4 | 10 |
| 6 | Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. , 2021, 9, e001884. | | 27 |
| 7 | Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. <i>Clinical Cancer Research</i> , 2021, 27, 3845-3853. | 7.0 | 25 |
| 8 | Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydrataseâ€œDeficient Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 2910-2919. | 7.0 | 45 |
| 9 | High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. <i>Molecular Cancer Research</i> , 2021, 19, 1510-1521. | 3.4 | 20 |
| 10 | Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e178-e183. | 1.9 | 2 |
| 11 | Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5595-5606. | 7.0 | 12 |
| 12 | A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4994-5003. | 7.0 | 24 |
| 13 | Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma. <i>Cancer</i> , 2021, 127, 3946-3956. | 4.1 | 12 |
| 14 | Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6687-6695. | 7.0 | 25 |
| 15 | In silico modeling of combination systemic therapy for advanced renal cell carcinoma. , 2021, 9, e004059. | | 5 |
| 16 | The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. <i>European Urology Oncology</i> , 2020, 3, 47-56. | 5.4 | 20 |
| 17 | Everolimus plus bevacizumab is an effective firstâ€œline treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. <i>Cancer</i> , 2020, 126, 5247-5255. | 4.1 | 22 |
| 18 | Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. <i>British Journal of Cancer</i> , 2020, 123, 1590-1598. | 6.4 | 57 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. Nature Communications, 2020, 11, 4168. | 12.8 | 46 |
| 20 | DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy. , 2020, 8, e000230. | | 37 |
| 21 | Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression. Clinical Cancer Research, 2020, 26, 3629-3640. | 7.0 | 30 |
| 22 | PTEN Expression, Not Mutation Status in <i>TSC1</i> , <i>TSC2</i> , or <i>mTOR</i> , Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial. Clinical Cancer Research, 2019, 25, 506-514. | 7.0 | 31 |
| 23 | Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma. Cancer Discovery, 2019, 9, 1349-1357. | 9.4 | 226 |
| 24 | A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. Clinical Cancer Research, 2019, 25, 5202-5211. | 7.0 | 26 |
| 25 | Towards individualized therapy for metastatic renal cell carcinoma. Nature Reviews Clinical Oncology, 2019, 16, 621-633. | 27.6 | 148 |
| 26 | A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma. Cancer, 2019, 125, 2400-2408. | 4.1 | 18 |
| 27 | A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations. Clinical Cancer Research, 2019, 25, 2699-2707. | 7.0 | 98 |
| 28 | Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial. Cancer Discovery, 2019, 9, 510-525. | 9.4 | 169 |
| 29 | Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science, 2018, 359, 801-806. | 12.6 | 898 |
| 30 | Up-front Nivolumab With or Without Salvage Ipilimumab Across International Metastatic Database Consortium Risk Groups in Metastatic Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 0, , . | 1.6 | 0 |